Phenibut — The GABA-B Agonist
Phenibut is a synthetic derivative of the inhibitory neurotransmitter GABA, modified with a phenyl ring to allow it to cross the blood-brain barrier. While developed as an anxiolytic and nootropic, it has no established role in longevity medicine and is primarily noted for its effects on stress reduction and sleep architecture.
Mechanism of Action
Phenibut acts primarily as an agonist at metabotropic GABA-B receptors, similar to baclofen, and at higher doses, it may also stimulate GABA-A receptors. Additionally, it binds to the α2δ subunit of voltage-dependent calcium channels, sharing a mechanism with gabapentinoids. This dual action reduces neuronal excitability, dampens the release of excitatory neurotransmitters like glutamate, and modulates dopamine release. These pathways collectively lower central nervous system arousal, which can mitigate acute stress but does not directly engage canonical longevity pathways such as mTOR, AMPK, or sirtuins.
Human Trial Evidence
No published human longevity trials. Clinical evidence is limited to its use as an anxiolytic and nootropic in Eastern Europe, where it has been studied for stress, insomnia, and cognitive function. There is no robust human data supporting its use for lifespan extension or healthspan improvement.
Dosing Protocol
250–500 mg per day is the typical clinical dose used in Eastern Europe for anxiety, though recreational doses often exceed this. It is not approved for medical use in the US or Western Europe. Due to rapid tolerance and severe withdrawal risks, continuous daily use is strongly discouraged.
Safety & Contraindications
Phenibut carries a high risk of tolerance, dependence, and severe withdrawal symptoms, including rebound anxiety, insomnia, and hallucinations. It is contraindicated with alcohol, benzodiazepines, and other CNS depressants due to the risk of respiratory depression. Not recommended for longevity purposes due to its abuse potential and lack of safety data for long-term use.